“ctDNA clearance is useful for seeing potential benefit in novel therapeutic studies.”
Emerik Osterlund, MD, PhD
New data from MD Anderson Cancer Center’s INTERCEPT Program, presented at ESMO Congress 2025, show that adjuvant therapy can clear ctDNA in a portion of CRC patients, leading to significantly better disease-free survival (DFS).
Key Findings:
🔹 26% of ctDNA-positive patients achieved clearance after adjuvant therapy
🔹 Clearance on ≥2 tests correlated with superior DFS
🔹 Spontaneous ctDNA clearance was rare and short-lived
These results support ctDNA clearance as a valuable endpoint for evaluating new CRC treatments and monitoring minimal residual disease.
Read the full news article on CancerNetwork.
